Pharma Sector Check - Can Indian Generic Players Mitigate The Revlimid Cliff? Systematix

Sun Pharma and Cipla better poised to mitigate the Revlimid cliff.

<div class="paragraphs"><p>Various medicines arranged for photograph. (Source: freepik)</p></div>
Various medicines arranged for photograph. (Source: freepik)

BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Systematix Research Report

gRevlimid launch has helped Indian players ramp up their North America sales meaningfully. For companies under our coverage (Cipla Ltd., Dr. Reddy's Laboratories Ltd., Lupin Ltd., Sun Pharmaceutical Industries Ltd., and Zydus Lifesciences Ltd., we estimate the cumulative contribution from gRevlimid at $800-$900 million.

In addition to gRevlimid, these companies aslo generate signficant sales from other high-value products, which are essentially complex generics. We estimate these high value products including gRevlimid and complex generics contribute close to $1.7 billion to the U.S. sales for these companies.

The contribution of these products to the total profit is disproportionately high. Our attempt in this report is to estimate if the contribution of these high-value assets would remain stable, expand or erode in FY27 (once the Revlimid settlement exclusivity expires).

Our analysis suggests that in an optimistic scenario, sales may stay flat, but in a more likey scenario, the same could erode.

The pressure from erosion could vary across companies, but on a consolidated basis, U.S. sales could face pressure on growth.

Click on the attachment to read the full report:

Systematix - Pharmaceuticals - Sector Update.pdf
Tatva Chintan Pharma Chem - Core Business Normalising; New Products Pipeline Maturing: ICICI Securities


This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.